{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032028","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-08-10T20:17:18+00:00","discovered_at":"2026-08-10T20:18:18.516286+00:00","generated_at":"2026-08-10T20:18:24.256377+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rocket Pharma Q2 net income $123.2M on PRV sale; cash $283.7M, runway to Q2 2028","bullets":["Net income $123.2M ($1.09 basic EPS) vs net loss $68.9M ($0.62 loss) in Q2 2025.","Other income $178.8M includes $178.2M net from Rare Pediatric Disease PRV sale (closed June 12, 2026).","RP-A501: all 3 initial Danon disease patients completed safety observation; no TMA or capillary leak.","KRESLADI (LAD-I) FDA approved; commercial availability and patient onboarding expected Q4 2026.","Cash $283.7M at June 30, 2026; expected to fund operations into Q2 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032028","json":"https://secwatch.observer/filing/0001140361-26-032028.json","markdown":"https://secwatch.observer/filing/0001140361-26-032028.md","text":"https://secwatch.observer/filing/0001140361-26-032028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/0001140361-26-032028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:18:24.256377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}